

A single center open-label uncontrolled study to investigate tumour response and vascularization changes in neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable renal cell cancer

Submission date 14/02/2006	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 14/02/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 31/07/2009	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr S.A. Lagerveld-Zaaijer

Contact details
Academic Medical Center (AMC)
Department of Urology
P.O. Box 22660
Amsterdam
Netherlands
1100 DD
+31 (0)20 5666030
S.A.Zaaijer@amc.uva.nl

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Study objectives

In view of good pre-clinical and clinical results, it is thought that patients with renal cell cancer will benefit from BAY 43-9006 in a neoadjuvant setting. We anticipate a benefit with the treatment of BAY 43-9006 when there is a tumour reduction more than 30%.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Single center open-label uncontrolled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Renal cell cancer

Interventions

All patients will receive BAY 43-9006 400 mg twice a day (bid) for the period of 8 weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

BAY 43-9006 [sorafenib (Nexavar®)]

Primary outcome(s)

Parameters: tumour response and vascularization.

1. Tumour reduction measured by CT
2. Quantitative changes in perfusion as measured by means of contrast enhanced ultrasound and various image processing techniques

Key secondary outcome(s))

Parameters: toxicity.

1. Toxicity by means of the remaining laboratory assessments
2. Number and severity of adverse events (AEs)
3. Number and severity of serious adverse events (SAEs)

Completion date

01/07/2008

Eligibility

Key inclusion criteria

1. Patients >18 years
2. Eastern Cooperative Oncology Group (ECOG) = 1 (2)
3. Candidates for a radical or partial nephrectomy who are fit for surgery
4. At least one uni-dimensional measurable lesion, measured by computed tomography (CT) scan
5. Adequate bone marrow function
6. Adequate liver function
7. Adequate renal function
8. Adequate coagulation
9. Men and women must have adequate barrier birth control before and during and for 1 week after the trial
10. Signed informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY43- 9006
2. History of cardiac disease, congestive heart failure, cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension
3. History of chronic hepatitis B or C and HIV infection
4. Patients with seizure disorders (requiring medication)
5. Patients with evidence or history of bleeding diathesis
6. Other investigational drug therapy within 30 days
7. Women of childbearing potential with a positive pregnancy test within 7 days before start treatment

8. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
9. Unable to swallow oral medication
10. Tumour/disease specific criteria: chronic diarrhoea, bowel obstruction, degree of malnutrition, malabsorption
11. Major surgery within 4 weeks before screening

Date of first enrolment

01/03/2006

Date of final enrolment

01/07/2008

Locations

Countries of recruitment

Netherlands

Study participating centre

Academic Medical Center (AMC)

Amsterdam

Netherlands

1100 DD

Sponsor information

Organisation

Academic Medical Center (AMC), Department of Urology (The Netherlands)

ROR

<https://ror.org/03t4gr691>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Academic Medical Center (AMC), Department of Urology (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration